Literature DB >> 36266604

A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration.

Shoichiro Mizukami1, Tatsuya Shonaka2, Chikayoshi Tani1, Kazuki Ihara1, Tomohiro Takeda1, Mizuho Ohara1, Kimiharu Hasegawa1, Mishie Tanino3, Koji Sawada4, Yasuo Sumi1.   

Abstract

Capecitabine and oxaliplatin (CAPOX) plus bevacizumab (BEV) therapy (CAPOX/BEV) is a standard treatment recommended as the first-line treatment for colorectal cancer recurrence. Recently, sinusoidal obstruction syndrome (SOS) and resulting portal hypertension have been reported as important side effects of oxaliplatin. We herein report a rectal cancer patient who underwent percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) for stomal variceal bleeding and splenomegaly due to portal hypertension caused by SOS after CAPOX therapy. A 43-year-old man who underwent robot-assisted laparoscopic abdominoperineal resection for advanced lower rectal cancer was started on CAPOX/BEV therapy for early recurrence 1 month after surgery. In the sixth course, splenomegaly rapidly worsened, stomal varices appeared, and the stoma began bleeding. At 5 months after the appearance of stomal varices, the splenomegaly worsened, the frequency of stomal bleeding increased, and PTO was performed. Five months later, PSE was performed for splenomegaly and thrombocytopenia. At 5 months since the PSE, the stoma bleeding has not recurred, and the thrombocytopenia has been corrected. The patient has been able to continue chemotherapy. We suggest that staged treatment by PTO and PSE be considered an important treatment option for stomal varices and splenomegaly associated with SOS.
© 2022. The Author(s).

Entities:  

Keywords:  Oxaliplatin; Sinusoidal obstruction syndrome; Stomal varices

Year:  2022        PMID: 36266604     DOI: 10.1007/s12328-022-01720-7

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  39 in total

Review 1.  The role of the endothelium in the short-term complications of hematopoietic SCT.

Authors:  E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2011-04-04       Impact factor: 5.483

2.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.

Authors:  Jean-Nicolas Vauthey; Timothy M Pawlik; Dario Ribero; Tsung-Teh Wu; Daria Zorzi; Paulo M Hoff; Henry Q Xiong; Cathy Eng; Gregory Y Lauwers; Mari Mino-Kenudson; Mauro Risio; Andrea Muratore; Lorenzo Capussotti; Steven A Curley; Eddie K Abdalla
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

3.  Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography.

Authors:  Agostino Colli; Pietro Pozzoni; Alessandra Berzuini; Alessandro Gerosa; Cristina Canovi; Edoardo Ennio Molteni; Marco Barbarini; Ferruccio Bonino; Daniele Prati
Journal:  Radiology       Date:  2010-10-08       Impact factor: 11.105

Review 4.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.

Authors:  Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B Thomas; Cathy Eng; David Z Chang; Steven A Curley; Eddie K Abdalla; Lee M Ellis; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

7.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

Authors:  Catherine Hubert; Christine Sempoux; Yves Horsmans; Jacques Rahier; Yves Humblet; Jean-Pascal Machiels; Antonino Ceratti; Jean-Luc Canon; Jean-François Gigot
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

Review 9.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; R F Duarte; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; T Pagluica; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; E Carreras
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

10.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; F Dignan; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; S Okamoto; A Pagliuca; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; R F Duarte; E Carreras
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.